Read about our groundbreaking advancements:
- Structure–Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants
- Development of Semisynthetic Saponin Immunostimulants
- Potentiating Pneumococcal Glycoconjugate Vaccine PCV13 with Saponin Adjuvant VSA-1
- Natural and Synthetic Saponins as Vaccine Adjuvants
- Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination
- Structural Effect on Adjuvanticity of Saponins
- Impact of C28 Oligosaccharide on Adjuvant Activity of QS-7 Analogues
- Vaccine Adjuvants Derivatized from Momordica Saponins I and II
- Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant
- Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants
- Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide
- Synthesis of QS-21-Based Immunoadjuvants
At Adjuvax, we are dedicated to developing potent, cost-effective, structurally defined, and highly accessible saponin adjuvants with diverse activity profiles tailored to various vaccine applications.
Stay Connected: